Kestra raises FY26 revenue guidance to $91M while targeting 70%+ gross margins with ASSURE system expansion

Kestra Medical Technologies raised its FY26 revenue guidance to $91M, targeting 70%+ gross margins with the ASSURE system expansion. Q2 2026 revenue was $22.6M, a 53% increase year-over-year, with a gross margin of 50.6%. The company plans to expand sales territories and increase prescriptions, supported by clinical evidence from the ACE-PAS study. Operating expenses were $43.2M, with a GAAP net loss of $(32.8) M. Kestra aims for continued growth and improved margins over the next few years.